RT @BiotechMania: CAR-T細胞療法後の再発・耐性獲得メカニズムの論文が出ています。 https://t.co/nEmSCBZHcb
RT @EricTopol: On the day when @NobelPrize recognizes #cancer immunotherapy, new insights about resistance to chimeric antigen receptor T c…
RT @EricTopol: On the day when @NobelPrize recognizes #cancer immunotherapy, new insights about resistance to chimeric antigen receptor T c…
Mutations driving CAR escape. https://t.co/1WeX7ozYjX
RT @EricTopol: On the day when @NobelPrize recognizes #cancer immunotherapy, new insights about resistance to chimeric antigen receptor T c…
RT @EricTopol: On the day when @NobelPrize recognizes #cancer immunotherapy, new insights about resistance to chimeric antigen receptor T c…
RT @EricTopol: On the day when @NobelPrize recognizes #cancer immunotherapy, new insights about resistance to chimeric antigen receptor T c…
RT @EricTopol: On the day when @NobelPrize recognizes #cancer immunotherapy, new insights about resistance to chimeric antigen receptor T c…
RT @EricTopol: On the day when @NobelPrize recognizes #cancer immunotherapy, new insights about resistance to chimeric antigen receptor T c…
RT @EricTopol: On the day when @NobelPrize recognizes #cancer immunotherapy, new insights about resistance to chimeric antigen receptor T c…
RT @EricTopol: On the day when @NobelPrize recognizes #cancer immunotherapy, new insights about resistance to chimeric antigen receptor T c…
RT @FJCarmonas: A recent paper in @NatureMedicine reports an extremely rare case of resistance to #CARTcell therapy in a #leukemia patient…
A recent paper in @NatureMedicine reports an extremely rare case of resistance to #CARTcell therapy in a #leukemia patient resulting from a defect in the manufacturing process. Need to optimize technology to avoid detrimental effects for #cancer patients –
RT @EricTopol: On the day when @NobelPrize recognizes #cancer immunotherapy, new insights about resistance to chimeric antigen receptor T c…
RT @EricTopol: On the day when @NobelPrize recognizes #cancer immunotherapy, new insights about resistance to chimeric antigen receptor T c…
RT @EricTopol: On the day when @NobelPrize recognizes #cancer immunotherapy, new insights about resistance to chimeric antigen receptor T c…
RT @AndyBiotech: Two new papers out in @NatureMedicine on CD19 CAR-T relapse and resistance mechanisms Penn's infamous CAR-B case https:/…
RT @EricTopol: On the day when @NobelPrize recognizes #cancer immunotherapy, new insights about resistance to chimeric antigen receptor T c…
RT @EricTopol: On the day when @NobelPrize recognizes #cancer immunotherapy, new insights about resistance to chimeric antigen receptor T c…
RT @EricTopol: On the day when @NobelPrize recognizes #cancer immunotherapy, new insights about resistance to chimeric antigen receptor T c…
..pero... esperemos que las prisas no hagan una burbuja de la inmunoterapia que nos estalle como otras tantas veces ocurre. https://t.co/MgJ0pC1SPi #immunotherapy #immunoOncology
RT @EricTopol: On the day when @NobelPrize recognizes #cancer immunotherapy, new insights about resistance to chimeric antigen receptor T c…
On the day when @NobelPrize recognizes #cancer immunotherapy, new insights about resistance to chimeric antigen receptor T cell therapy https://t.co/uISznRTMJC https://t.co/nQEYxS3NYt @NatureMedicine https://t.co/QBSzfzeCzr
RT @AndyBiotech: Two new papers out in @NatureMedicine on CD19 CAR-T relapse and resistance mechanisms Penn's infamous CAR-B case https:/…
RT @AndyBiotech: Two new papers out in @NatureMedicine on CD19 CAR-T relapse and resistance mechanisms Penn's infamous CAR-B case https:/…
RT @AndyBiotech: Two new papers out in @NatureMedicine on CD19 CAR-T relapse and resistance mechanisms Penn's infamous CAR-B case https:/…
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia https://t.co/RNMY5zqSOI #clinicaltrials https://t.co/1h8NrgJXLK
RT @AndyBiotech: Two new papers out in @NatureMedicine on CD19 CAR-T relapse and resistance mechanisms Penn's infamous CAR-B case https:/…
RT @AndyBiotech: Two new papers out in @NatureMedicine on CD19 CAR-T relapse and resistance mechanisms Penn's infamous CAR-B case https:/…
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia https://t.co/VIi0dbFX0J https://t.co/PtlTKUxh2T
RT @AndyBiotech: Two new papers out in @NatureMedicine on CD19 CAR-T relapse and resistance mechanisms Penn's infamous CAR-B case https:/…
RT @AndyBiotech: Two new papers out in @NatureMedicine on CD19 CAR-T relapse and resistance mechanisms Penn's infamous CAR-B case https:/…
RT @AndyBiotech: Two new papers out in @NatureMedicine on CD19 CAR-T relapse and resistance mechanisms Penn's infamous CAR-B case https:/…
RT @AndyBiotech: Two new papers out in @NatureMedicine on CD19 CAR-T relapse and resistance mechanisms Penn's infamous CAR-B case https:/…
CAR-T細胞療法後の再発・耐性獲得メカニズムの論文が出ています。
RT @AndyBiotech: Two new papers out in @NatureMedicine on CD19 CAR-T relapse and resistance mechanisms Penn's infamous CAR-B case https:/…
RT @AndyBiotech: Two new papers out in @NatureMedicine on CD19 CAR-T relapse and resistance mechanisms Penn's infamous CAR-B case https:/…
RT @AndyBiotech: Two new papers out in @NatureMedicine on CD19 CAR-T relapse and resistance mechanisms Penn's infamous CAR-B case https:/…
Two new papers out in @NatureMedicine on CD19 CAR-T relapse and resistance mechanisms Penn's infamous CAR-B case https://t.co/zcj5MwSAuN NIBR analysis suggests acquired mutations in CD19 exons 2–5 leading to antigen loss https://t.co/azcvn0ToEb $NVS $GI